Evidence map›Paper›PMID 33229895›Full record

ArticleAIDS (London, England)2021

Factors associated with worse cerebrovascular function in aging women with and at risk for HIV.

Felicia C Chow, Yifei Ma, Maura Manion, Adam Rupert, Geralyn Lambert-Messerlian, Cheryl D Bushnell, Marcelle I Cedars, Irini Sereti, Farzaneh A Sorond, Priscilla Y Hsue and 1 more

Open access · greenAbstract read
In one paragraph

Article in AIDS (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Felicia C ChowWeill Institute for Neurosciences, Department of Neurology, University of California, San Francisco.
Yifei MaDepartment of Medicine, University of California, San Francisco, San Francisco, California.
Maura ManionLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Adam RupertAIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Geralyn Lambert-MesserlianDepartments of Pathology and Laboratory Medicine and Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island, Providence, Rhode Island.
Cheryl D BushnellDepartment of Neurology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Marcelle I CedarsDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California.
Irini SeretiLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Farzaneh A SorondDepartment of Neurology, Northwestern University, Chicago, Illinois.
Priscilla Y HsueDepartment of Medicine, Division of Cardiology, San Francisco General Hospital, University of California, San Francisco.
Phyllis C TienDepartment of Medicine, Division of Infectious Diseases, University of California, San Francisco.
University of California, San Francisco · USNational Institutes of Health · USFrederick National Laboratory for Cancer Research · USNorthwestern University · USSan Francisco General Hospital · USSan Francisco VA Medical Center · USWake Forest University · USWomen & Infants Hospital of Rhode Island · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Immunopathogenic Mechanisms of Human Immunodeficiency Virus (HIV) DiseaseZIAAI001121 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SERETI, IRINI · 2010 to 2025
$27.2M
Institutional Career Development Core SupplementKL2TR001870 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANAYA, ALKA M., SARKAR, URMIMALA · 2016 to 2025
$19.7M
Clinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9M
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV InfectionR01HL152957 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PETER W HUNT, Priscilla Y. Hsue · 2020 to 2026
$3.7M
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging WomenR01DA044111 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KOVACS, ANDREA A.Z., TIEN, PHYLLIS C · 2017 to 2021
$3.5M
Role of Hematopoietic System and Proteomics in HIV-Associated CardiovascularDiseaseK24AI112393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSUE, PRISCILLA Y. · 2014 to 2024
$1.9M
HIV, HCV, and gender effects on Liver, Bone, and Vascular HealthK24AI108516 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TIEN, PHYLLIS C · 2013 to 2024
$1.5M
Effects of the neural and inflammatory response to stress on cerebrovascular risk in HIV infectionK23NS105575 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, FELICIA C. · 2017 to 2021
$1.0M
NCATS NIH HHS KL2 TR000143NCATS NIH HHS KL2 TR001870NHLBI NIH HHS R01 HL152957NHLBI NIH HHS U01 HL146242NIAID NIH HHS K24 AI108516NIAID NIH HHS K24 AI112393NIAID NIH HHS P30 AI027763NIDA NIH HHS R01 DA044111NINDS NIH HHS K23 NS105575
6 · The paper itself

Abstract

objectiveWomen may be disproportionately impacted by the negative effect of HIV on cerebrovascular risk. We examined the association of HIV, sex, menopause, and immune activation with cerebrovascular function among women with HIV (WWH) and at risk for HIV from the Women's Interagency HIV Study and men with HIV.

designCross-sectional.

methodsParticipants were aged at least 40 years with coronary heart disease or at least one cardiometabolic risk factor. All persons with HIV were on antiretroviral therapy with undetectable viral load. Cerebral vasoreactivity was assessed by the transcranial Doppler breath-holding test, with lower vasoreactivity corresponding to worse cerebrovascular function. Menopausal status was determined by anti-Müllerian hormone level. We used mixed effects linear regression to identify factors associated with cerebral vasoreactivity.

resultsMean cerebral vasoreactivity was similar in WWH (n = 33) and women at risk for HIV (n = 16). A trend toward higher cerebral vasoreactivity in WWH compared with men with HIV (n = 37) was no longer present after excluding women on estrogen replacement therapy (n = 3). In women, menopausal status was not significantly associated with cerebral vasoreactivity. WWH with higher cardiovascular risk (-0.14 for each additional cardiometabolic risk factor, P = 0.038), sCD163 (-0.20 per doubling, P = 0.033), and proportion of CD4+CX3CR1+ T cells (-0.14 per doubling, P = 0.028) had lower cerebral vasoreactivity.

conclusionAmong older women at high cardiovascular risk, women with virologically suppressed HIV and women at risk for HIV had similar cerebrovascular function. Our findings, which must be interpreted in the context of the small sample, highlight the contribution of traditional cardiometabolic risk factors and immune activation to cerebrovascular risk in WWH.

Indexed as

HIV InfectionsAgedAgingChildCross-Sectional StudiesFemaleHumansMaleMenopauseRisk FactorsViral Load

Identifiers

PMID33229895
PMCPMC7789911
OpenAlexW3110578678

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.